Shopping Cart 0
Cart Subtotal
USD 0

Dilated Cardiomyopathy - Pipeline Review, H1 2019

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Dilated Cardiomyopathy-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy-Pipeline Review, H1 2019, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape.

Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include Fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention and swelling (edema) in legs, ankles and feet. Risk factors include family history, alcoholism, hypertension, cocaine abuse and metabolic disorders, such as thyroid disease or diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dilated Cardiomyopathy-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Dilated Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Dilated Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Dilated Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Dilated Cardiomyopathy (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Dilated Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Dilated Cardiomyopathy-Overview

Dilated Cardiomyopathy-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Dilated Cardiomyopathy-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dilated Cardiomyopathy-Companies Involved in Therapeutics Development

Array BioPharma Inc

Capricor Therapeutics Inc

Celixir Ltd

Hemostemix Inc

Martin Pharmaceuticals Inc

MyoKardia Inc

Dilated Cardiomyopathy-Drug Profiles

ACP-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARRY-797-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BC-007-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAP-1002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCM-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate BAG3 for Dilated Cardiomyopathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heartcel-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LUS-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-440181-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Dilated Cardiomyopathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trimetazidine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YS-1402-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dilated Cardiomyopathy-Dormant Projects

Dilated Cardiomyopathy-Product Development Milestones

Featured News & Press Releases

Dec 11, 2018: MyoKardia reports positive data from phase 1b single-ascending dose clinical trial of MYK-491 in dilated cardiomyopathy and systolic heart failure patients

Dec 06, 2018: Berlin Cures steering committee is assembled to facilitate the design and implementation of phase 2 study of BC 007

Oct 30, 2018: MyoKardia Shares Data from new research program ACT-1 at 2018 R&D Day

Feb 26, 2018: Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study

Feb 14, 2018: MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients

Nov 02, 2017: MyoKardia Provides Update on MYK-491

Sep 27, 2017: MyoKardia Provides Update on MYK-491 Clinical Progress

Feb 02, 2017: First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491

Dec 02, 2016: MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491

Aug 30, 2016: Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress

Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Dilated Cardiomyopathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Dilated Cardiomyopathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Dilated Cardiomyopathy-Pipeline by Array BioPharma Inc, H1 2019

Dilated Cardiomyopathy-Pipeline by Capricor Therapeutics Inc, H1 2019

Dilated Cardiomyopathy-Pipeline by Celixir Ltd, H1 2019

Dilated Cardiomyopathy-Pipeline by Hemostemix Inc, H1 2019

Dilated Cardiomyopathy-Pipeline by Martin Pharmaceuticals Inc, H1 2019

Dilated Cardiomyopathy-Pipeline by MyoKardia Inc, H1 2019

Dilated Cardiomyopathy-Dormant Projects, H1 2019

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Dilated Cardiomyopathy Therapeutic Products under Development, Key Players in Dilated Cardiomyopathy Therapeutics, Dilated Cardiomyopathy Pipeline Overview, Dilated Cardiomyopathy Pipeline, Dilated Cardiomyopathy Pipeline Assessment


Companies

Array BioPharma Inc

Capricor Therapeutics Inc

Celixir Ltd

Hemostemix Inc

Martin Pharmaceuticals Inc

MyoKardia Inc

Dilated Cardiomyopathy-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy-Pipeline Review, H1 2019, provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape.

Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. Symptoms include Fatigue and weakness, Shortness of breath (dyspnea), lightheadedness, dizziness or fainting, persistent cough or wheezing, lack of appetite, sudden weight gain from fluid retention and swelling (edema) in legs, ankles and feet. Risk factors include family history, alcoholism, hypertension, cocaine abuse and metabolic disorders, such as thyroid disease or diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dilated Cardiomyopathy-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Dilated Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Dilated Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Dilated Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Dilated Cardiomyopathy (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Dilated Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Dilated Cardiomyopathy-Overview

Dilated Cardiomyopathy-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Dilated Cardiomyopathy-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dilated Cardiomyopathy-Companies Involved in Therapeutics Development

Array BioPharma Inc

Capricor Therapeutics Inc

Celixir Ltd

Hemostemix Inc

Martin Pharmaceuticals Inc

MyoKardia Inc

Dilated Cardiomyopathy-Drug Profiles

ACP-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARRY-797-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BC-007-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAP-1002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCM-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate BAG3 for Dilated Cardiomyopathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heartcel-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LUS-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-440181-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Dilated Cardiomyopathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Myocardial Infarction and Dilated Cardiomyopathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trimetazidine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YS-1402-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dilated Cardiomyopathy-Dormant Projects

Dilated Cardiomyopathy-Product Development Milestones

Featured News & Press Releases

Dec 11, 2018: MyoKardia reports positive data from phase 1b single-ascending dose clinical trial of MYK-491 in dilated cardiomyopathy and systolic heart failure patients

Dec 06, 2018: Berlin Cures steering committee is assembled to facilitate the design and implementation of phase 2 study of BC 007

Oct 30, 2018: MyoKardia Shares Data from new research program ACT-1 at 2018 R&D Day

Feb 26, 2018: Heart Failure Treatment from Berlin Cures Shows Promise in Phase 1 Study

Feb 14, 2018: MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients

Nov 02, 2017: MyoKardia Provides Update on MYK-491

Sep 27, 2017: MyoKardia Provides Update on MYK-491 Clinical Progress

Feb 02, 2017: First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491

Dec 02, 2016: MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491

Aug 30, 2016: Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress

Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Dilated Cardiomyopathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Dilated Cardiomyopathy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Dilated Cardiomyopathy-Pipeline by Array BioPharma Inc, H1 2019

Dilated Cardiomyopathy-Pipeline by Capricor Therapeutics Inc, H1 2019

Dilated Cardiomyopathy-Pipeline by Celixir Ltd, H1 2019

Dilated Cardiomyopathy-Pipeline by Hemostemix Inc, H1 2019

Dilated Cardiomyopathy-Pipeline by Martin Pharmaceuticals Inc, H1 2019

Dilated Cardiomyopathy-Pipeline by MyoKardia Inc, H1 2019

Dilated Cardiomyopathy-Dormant Projects, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Dilated Cardiomyopathy Therapeutic Products under Development, Key Players in Dilated Cardiomyopathy Therapeutics, Dilated Cardiomyopathy Pipeline Overview, Dilated Cardiomyopathy Pipeline, Dilated Cardiomyopathy Pipeline Assessment


Companies

Array BioPharma Inc

Capricor Therapeutics Inc

Celixir Ltd

Hemostemix Inc

Martin Pharmaceuticals Inc

MyoKardia Inc